A Greek Real-World Experience With the Implementation of the EndoPredict Gene Signature in a Cohort of Pre-menopausal and Post-menopausal Patients With ER+/HER2- Breast Cancer.

Authors

George Pantazidis, Antigoni Sourla, Aggeliki Vasiageorgi, Christina Yfanti, Anna-Maria Alisandrou, Giasemi Stefanou, Aggelos Petsavas, Fotini Pavlidou, Styliani Parpoudi, Dimitrios Alexandrou, Anna Sachoulidou, Annezo Marinatou, Evgenia Kalogridaki, Theodoros Kontoulis, Panagiotis E Daskalakis, Vlassios Tsantilas, Stavros Chatzopoulos, Christos Kanistras, Theodoros Argyriou, Dimitrios Dragoumis, Vaia Stafyla, Konstantinos Louis, Andriana Kouloura, Ioanna Galanou, Georgios Papazoglou, Dimitrios Grosomanidis, Konstantinos Chatzopoulos, Georgia Pasaskevakou, Panagiota Varnava, Anna Giannopoulou, Xenofon Xenakis, Apostolos Mpakogiannis, Ioannis Flessas, Dimitrios Nasikas, Dimitrios Koronarchis, Stergios Douvetzemis, Ioannis Fyssas, Christos Spanopoulos, Dimosthenis Baltas, Dimitrios Keramopoulos, Konstantinos Bouloukos, Vilma Gaki, Dionysios T Dimas, Ioannis L Missitzis, Georgios Rigas, Christos Kalyvopoulos, Stavros Intzes, Stefanos Zervoudis, Europi Michailidou, Anastasios Katsourakis, Markos Thanos, Apostolos Zavos, George Boutsikos, Maria Kanara, Sotirios Α Rousogiannis, Panagiotis Charatsaris, Pavlos Lampropoulos, Sarantos Papadopoulos, Evangelos P Solakis, Ioannis Askoxylakis, Sofia Kakoulaki, Eleftherios Sfakianakis, Nikolaos Vrentzos, Despoina Milonaki, Ioannis Kyriasanos, Foivos Irakleidis, Rodoniki Iosifidou

Published in

Cureus. Volume 18. Issue 8. Pages e114838. Epub Aug 20, 2026.

Abstract

Background EndoPredict® is a guideline-recommended gene signature assay guiding whether adjuvant treatment should include chemotherapy or not. The EndoPredict® Clinical (EPclin) Risk Score combines molecular and clinical data to predict the distant recurrence of breast cancer, providing valuable information about the prognosis and chemotherapy benefit in both pre- and post-menopausal patients. Methodology This is a real-world, retrospective study aiming to characterize the EPclin Risk Score's utility in 200 consecutively selected Greek patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer, enrolled in a single institution, considering their clinicopathological features and menopausal status, with emphasis on its role in identifying patients suitable for treatment de-escalation. Results In this study, 100 pre-menopausal and 100 post-menopausal ER+/HER2- breast cancer patients were included. Among the pre-menopausal subgroup, 65% of the patients were classified as low risk and the other 35% as high risk, while among the post-menopausal subgroup, the low-risk and high-risk patients were 66% and 34%, respectively. A notable 30% of node-positive premenopausal patients were characterized by EPclin as at a low risk of breast cancer. Conclusions The EPclin Risk score has the ability to stratify and guide therapy decisions in ER+/HER2- breast cancer patients. It classifies the recurrence risk differently from traditional assessments and identifies low-risk premenopausal patients with node-positive disease. This may provide a de-escalation treatment pathway for such patients but requires further clinical validation.

PMID:
42763779
Bibliographic data and abstract were imported from PubMed on 20 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.